[
  {
    "ts": null,
    "headline": "Merck & Co., Inc. (MRK): Among Defensive Stocks Billionaire Ken Fisher is Betting On",
    "summary": "We recently published a list of 10 Defensive Stocks Billionaire Ken Fisher is Betting On. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other defensive stocks billionaire Ken Fisher is betting on. Ken Fisher, an American billionaire investor, author, and financial analyst, founded and runs Fisher […]",
    "url": "https://finnhub.io/api/news?id=b1f7b40807f6ac6b2a0c51c452032e8f09d9326b256a7cfceb28d6ad793d6592",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744150507,
      "headline": "Merck & Co., Inc. (MRK): Among Defensive Stocks Billionaire Ken Fisher is Betting On",
      "id": 133823464,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "We recently published a list of 10 Defensive Stocks Billionaire Ken Fisher is Betting On. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other defensive stocks billionaire Ken Fisher is betting on. Ken Fisher, an American billionaire investor, author, and financial analyst, founded and runs Fisher […]",
      "url": "https://finnhub.io/api/news?id=b1f7b40807f6ac6b2a0c51c452032e8f09d9326b256a7cfceb28d6ad793d6592"
    }
  },
  {
    "ts": null,
    "headline": "Apple, Nike share losses lead Dow's 250-point fall",
    "summary": "Apple, Nike share losses lead Dow's 250-point fall",
    "url": "https://finnhub.io/api/news?id=30996f3f54b72dfeadbfa0746a0ce9b1581598024b166e79aa129ea9071d3c36",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744125000,
      "headline": "Apple, Nike share losses lead Dow's 250-point fall",
      "id": 133823018,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Apple, Nike share losses lead Dow's 250-point fall",
      "url": "https://finnhub.io/api/news?id=30996f3f54b72dfeadbfa0746a0ce9b1581598024b166e79aa129ea9071d3c36"
    }
  },
  {
    "ts": null,
    "headline": "Walgreens, CVS, & US drugmakers make big moves: What to know",
    "summary": "Walgreens (WBA) stock is rising after the company reported better-than-expected second quarter earnings while preparing for privatization. Yahoo Finance Senior Health Reporter Anjalee Khemlani highlights the company's cost management strategy, CVS's (CVS) leadership changes amid similar challenges in the retail drug sector, and moves by US drug makers, like Merck (MRK), Johnson & Johnson (JNJ), and Eli Lilly (LLY), as they prepare for incoming tariffs. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.",
    "url": "https://finnhub.io/api/news?id=4802859d758f4365de19e8df750d7be4ad395ac3a31a609b767e157d6ab882c0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744120998,
      "headline": "Walgreens, CVS, & US drugmakers make big moves: What to know",
      "id": 133811150,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Walgreens (WBA) stock is rising after the company reported better-than-expected second quarter earnings while preparing for privatization. Yahoo Finance Senior Health Reporter Anjalee Khemlani highlights the company's cost management strategy, CVS's (CVS) leadership changes amid similar challenges in the retail drug sector, and moves by US drug makers, like Merck (MRK), Johnson & Johnson (JNJ), and Eli Lilly (LLY), as they prepare for incoming tariffs. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.",
      "url": "https://finnhub.io/api/news?id=4802859d758f4365de19e8df750d7be4ad395ac3a31a609b767e157d6ab882c0"
    }
  },
  {
    "ts": null,
    "headline": "Q4 Earnings Roundup: Organon (NYSE:OGN) And The Rest Of The Branded Pharmaceuticals Segment",
    "summary": "Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Organon (NYSE:OGN) and the best and worst performers in the branded pharmaceuticals industry.",
    "url": "https://finnhub.io/api/news?id=3678b45cd73e254168e20a6b2de72c12af404d5b2a0635e001a5ec2f764683c5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744103238,
      "headline": "Q4 Earnings Roundup: Organon (NYSE:OGN) And The Rest Of The Branded Pharmaceuticals Segment",
      "id": 133823467,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Organon (NYSE:OGN) and the best and worst performers in the branded pharmaceuticals industry.",
      "url": "https://finnhub.io/api/news?id=3678b45cd73e254168e20a6b2de72c12af404d5b2a0635e001a5ec2f764683c5"
    }
  }
]